Neurogene Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Neurogene Inc. (NGNE) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $4.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-11
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $4.09M, a 88.54% increase year-over-year.
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $359.00K.
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.33M.
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $365.00K, a 86.18% decline year-over-year.
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $1.67M.
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$2.77M.
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$3.57M, a 543.42% decline from fiscal 2022.
- Neurogene Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $806.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.45M 10-Q · filed 2026-08-11 | $5.79M derived: sum of 3 quarters · filed 2026-08-11 | $6.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $359.00K 10-Q · filed 2026-05-12 | $1.69M derived: sum of 2 quarters · filed 2026-05-12 | $2.06M derived: sum of 3 quarters · filed 2026-05-12 | $4.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.70M derived: sum of 2 quarters · filed 2026-03-24 | $3.87M derived: sum of 3 quarters · filed 2026-08-11 | $1.67M 10-K · filed 2026-03-24 |
| 2025-09-30 | $365.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.54M derived: sum of 2 quarters · filed 2026-08-11 | $334.00K 10-Q · filed 2025-11-13 | -$409.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$31.00K 10-Q · filed 2026-08-11 | -$774.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$2.20M 10-Q · filed 2026-05-12 | -$2.95M derived: sum of 2 quarters · filed 2026-05-12 | -$304.00K derived: sum of 3 quarters · filed 2026-05-12 | -$97.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$743.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.90M derived: sum of 2 quarters · filed 2026-03-24 | $2.11M derived: sum of 3 quarters · filed 2026-03-24 | -$2.77M 10-K · filed 2026-03-24 |
| 2024-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.85M derived: sum of 2 quarters · filed 2025-11-13 | -$2.03M 10-Q · filed 2025-11-13 | -$5.69M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $207.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$4.67M 10-Q · filed 2025-08-11 | -$8.33M derived: sum of 3 quarters · filed 2025-08-11 | -$6.96M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$4.88M 10-Q · filed 2025-05-09 | -$8.54M derived: sum of 2 quarters · filed 2025-05-09 | -$7.17M derived: sum of 3 quarters · filed 2025-05-09 | -$6.01M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$2.29M derived: sum of 2 quarters · filed 2025-03-24 | -$1.13M derived: sum of 3 quarters · filed 2025-03-24 | -$3.57M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $2.53M derived: sum of 2 quarters · filed 2024-11-18 | $88.00K 10-Q · filed 2024-11-18 | |
| 2023-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$1.29M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | -$2.44M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $806.00K 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |